Syneos Health (NASDAQ:SYNH) was upgraded by research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Monday, February 4th.
A number of other equities analysts have also weighed in on the stock. Robert W. Baird set a $60.00 target price on shares of Syneos Health and gave the stock a “buy” rating in a research note on Tuesday, January 8th. Zacks Investment Research lowered shares of Syneos Health from a “buy” rating to a “hold” rating in a research note on Saturday, January 5th. UBS Group initiated coverage on shares of Syneos Health in a research note on Tuesday, October 9th. They issued a “buy” rating and a $60.00 target price for the company. SunTrust Banks reduced their target price on shares of Syneos Health to $55.00 and set a “buy” rating for the company in a research note on Wednesday, December 19th. Finally, Barclays reduced their target price on shares of Syneos Health from $51.00 to $45.00 and set an “equal weight” rating for the company in a research note on Thursday, January 3rd. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $53.44.
NASDAQ SYNH traded up $1.64 on Monday, reaching $43.41. The company had a trading volume of 1,912,906 shares, compared to its average volume of 461,345. The firm has a market cap of $5.75 billion, a PE ratio of 22.38, a PEG ratio of 1.56 and a beta of 1.51. The company has a current ratio of 0.97, a quick ratio of 0.97 and a debt-to-equity ratio of 0.99. Syneos Health has a 1-year low of $34.40 and a 1-year high of $56.34.
In other news, CEO Alistair Macdonald sold 8,143 shares of the stock in a transaction dated Wednesday, February 13th. The shares were sold at an average price of $53.00, for a total transaction of $431,579.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Jonathan Olefson bought 750 shares of the business’s stock in a transaction that occurred on Monday, December 17th. The stock was purchased at an average price of $41.27 per share, with a total value of $30,952.50. The disclosure for this purchase can be found here. Corporate insiders own 0.57% of the company’s stock.
Large investors have recently modified their holdings of the stock. Enlightenment Research LLC acquired a new stake in Syneos Health in the 4th quarter valued at about $51,000. NumerixS Investment Technologies Inc acquired a new stake in Syneos Health in the 4th quarter valued at about $57,000. Bessemer Group Inc. acquired a new stake in Syneos Health in the 4th quarter valued at about $59,000. Oppenheimer Asset Management Inc. acquired a new stake in Syneos Health in the 4th quarter valued at about $66,000. Finally, Private Capital Group LLC lifted its stake in Syneos Health by 79.7% in the 4th quarter. Private Capital Group LLC now owns 1,824 shares of the company’s stock valued at $72,000 after purchasing an additional 809 shares during the last quarter.
Syneos Health Company Profile
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Read More: What is a back-end load?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.